Analysts Anticipate Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Will Announce Earnings of -$1.97 Per Share

Equities analysts expect that Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) will report earnings of ($1.97) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Biohaven Pharmaceutical’s earnings. The lowest EPS estimate is ($2.36) and the highest is ($1.60). Biohaven Pharmaceutical posted earnings per share of ($1.34) during the same quarter last year, which would indicate a negative year over year growth rate of 47%. The firm is scheduled to announce its next quarterly earnings report on Thursday, February 27th.

On average, analysts expect that Biohaven Pharmaceutical will report full-year earnings of ($9.88) per share for the current financial year, with EPS estimates ranging from ($10.40) to ($8.83). For the next financial year, analysts expect that the company will report earnings of ($6.78) per share, with EPS estimates ranging from ($8.71) to ($5.12). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Biohaven Pharmaceutical.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.47).

BHVN has been the topic of a number of recent research reports. Goldman Sachs Group set a $89.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Canaccord Genuity set a $80.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, August 26th. Morgan Stanley set a $50.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “hold” rating in a research note on Friday, August 9th. Oppenheimer set a $67.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, ValuEngine lowered shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $71.80.

NYSE:BHVN traded up $2.06 on Friday, reaching $51.08. 881,221 shares of the company’s stock were exchanged, compared to its average volume of 487,177. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of -8.31 and a beta of 0.34. The business has a fifty day moving average of $45.01 and a 200-day moving average of $47.68. Biohaven Pharmaceutical has a 52-week low of $29.17 and a 52-week high of $67.86.

In related news, insider Elyse Stock sold 17,700 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $45.07, for a total value of $797,739.00. Following the completion of the transaction, the insider now directly owns 17,700 shares of the company’s stock, valued at $797,739. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Eric Aguiar sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $45.00, for a total value of $450,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,500 shares of company stock valued at $1,283,747. Corporate insiders own 23.90% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in BHVN. Nuveen Asset Management LLC acquired a new position in Biohaven Pharmaceutical in the second quarter valued at approximately $38,799,000. Bank of New York Mellon Corp boosted its holdings in Biohaven Pharmaceutical by 236.8% in the second quarter. Bank of New York Mellon Corp now owns 545,594 shares of the company’s stock valued at $23,892,000 after purchasing an additional 383,594 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Biohaven Pharmaceutical by 60.7% in the second quarter. Brown Advisory Inc. now owns 1,008,046 shares of the company’s stock valued at $44,144,000 after purchasing an additional 380,764 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Biohaven Pharmaceutical by 34.2% in the second quarter. Vanguard Group Inc. now owns 1,154,257 shares of the company’s stock valued at $50,545,000 after purchasing an additional 294,098 shares in the last quarter. Finally, Luminus Management LLC acquired a new position in Biohaven Pharmaceutical in the second quarter valued at approximately $12,572,000. 88.91% of the stock is owned by hedge funds and other institutional investors.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Read More: Book Value Per Share in Stock Trading

Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.